Skip to main navigation Skip to search Skip to main content

Multiple Binding Sites for Small Molecule Antagonists at the Chemokine Receptor CCR2

  • A.J. Zweemer
  • , I. Nederpelt
  • , H. Vrieling
  • , S. Hafith
  • , M.L. Doornbos
  • , H. de Vries
  • , J. Abt
  • , R. Gross
  • , D. Stamos
  • , J. Saunders
  • , M.J. Smit
  • , A.P. IJzerman
  • , L.H. Heitman

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

The chemokine receptor CCR2 is a G protein-coupled receptor that is activated primarily by the endogenous CC chemokine ligand 2 (CCL2). Many different small-molecule antagonists have been developed to inhibit this receptor, as it is involved in a variety of diseases characterized by chronic inflammation. Unfortunately, all these antagonists lack clinical efficacy, and therefore a better understanding of their mechanism of action is warranted. In this study, we examined the pharmacological properties of small-molecule CCR2 antagonists in radioligand binding and functional assays. Six structurally different antagonists were selected for this study, all of which displaced the endogenous agonist
Original languageEnglish
Pages (from-to)551-561
JournalMolecular Pharmacology
Volume2013
Issue number84
DOIs
Publication statusPublished - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Multiple Binding Sites for Small Molecule Antagonists at the Chemokine Receptor CCR2'. Together they form a unique fingerprint.

Cite this